- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03076762
Comparative Study Suburothelial and Trigonal Botulinum Toxin A Injection in Treatment of Interstitial Cystitis
Comparative Study of the Efficacy and Safety Between Suburothelial and Trigonal Intravesical Botulinum Toxin A Injection in Treatment of Interstitial Cystitis Refractory to Conventional Treatment - A Prospective, Randomized, Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Introduction Interstitial cystitis/painful bladder syndrome (IC/PBS) is a debilitating chronic disease of unknown etiology characterized by urgency frequency and suprapubic pain at full bladder. Current treatments are usually unsuccessful in completely eradicating bladder pain and increasing bladder capacity. Intravesical resiniferatoxin once was considered to be effective but this has not been shown in a large scale multiple center trial. Several oral medication such as pentosanpolysulphate (PPS), amitryptynine, cyclosporin have been tried but the therapeutic efficacy have been proven ineffective. Intravesical treatment with heparin, hyaluronic acid, chondroitin sulphate, bacillus Calmette-Guerin, dimethylsulphoxide, resiniferatoxin, or botulinum toxin A has been shown early effectiveness in some patients. However, the placebo effect should be weighed and randomized, double-blind trials should be undertaken to demonstrate the actual therapeutic effects of these therapeutic modalities.
Although botulinum toxin type A (BoNT-A) has been widely reported in its efficacy in the treatment of neurogenic and idiopathic detrusor overactivity (DO) with satisfactory results, there have only been few studies using BoNT-A in treatment of IC/PBS. In recent basic researches, BoNT-A has been shown to inhibit not only the release of acetylcholine and norepinephrine, but also that of nerve growth factor, adenosine triphosphate, substance P and calcitonin gene-related peptide from the nerve fibers and urothelium. In clinical experiments, BoNT-A has been shown to reduce DO, impaired bladder sensation, and decrease visceral pain in chronic inflammatory diseases. These results suggest that BoNT-A treatment can modulate sensory transmission as well as reduce detrusor contractility. Although BoNT-A injection seems promising in treating symptoms of IC/PBS, long term results did not provide successful outcome. The limited successful result is possibly due to inadequate distribution of BoNT-A delivered to the bladder wall, inadequate dose of toxin, or lacking of some promoting factors to enhance the therapeutic effect of BoNT-A. Repeated intravesical BoNT-A injections was recently performed in refractory IC/PBS and the therapeutic effects seems promising. About 70% of the patients with non-ulcer type IC/PBS may benefit from repeated BoNT-A injections every 6 months. Immunohistochemistry study also confirmed the reduction of inflammatory biomarkers and pro-apoptotic proteins such as Bax and Bad expressions after repeated BoNT-A injections.
Concerning the injection sites of BoNT-A for IC/BPS bladders, there is no consensus. Suburothelial injection and Trigonal injection have all been used in treatment of IC/BPS and the short-term and long-term results are equivalent. It is unmet to clarify which injection method is superior in clinical efficacy and patient safety. This study was designed in a randomized, double-blind trial to test the therapeutic effects and adverse events between intravesical BoNTA injection into suburothelium and trigone. The results of this study might provide clinical evidence for a better therapeutic regimen of BoNT-A in the treatment of IC/PBS.
Materials and Methods
A total of 60 patients with IC/PBS who have failed previous treatments for at least 6 months will be enrolled in this study. A diagnosis of IC/PBS has been established based on characteristic symptoms and cystoscopic findings of glomerulations, petechia, or mucosal fissures after hydrodistention. All patients have been treated with at least two types of treatment modalities including non-steroid anti-inflammatory drugs, oral PPS, intravesical instillation of heparin, hyaluronic acid, or tricyclic antidepressant for at least 6 months but the symptoms remained unchanged or relapsed. They will be investigated thoroughly on enrollment and will be excluded if not meeting the inclusion criteria of NIDDK. However, in this study the patients with Hunner's ulcer will not be included because previous study has shown that ulcer type IC/BPS does not respond to intravesical BoNT-A injection.
Patients will be requested to keep a 3-day voiding diary prior to treatment to record the functional bladder capacity (FBC) and the number of urinary frequency and nocturnal. The IC symptoms will be assessed by the O'Leary-Sant symptom and problem indexes. The pain score will be reported by patient self-assessment using a 10-point visual analog scale (VAS) system. Videourodynamic study and potassium chloride (KCl) sensitivity test will be routinely performed and patients will be informed of the possible complications associated with BoNT-A injection such as generalized muscle weakness, difficult urination, transient urinary retention, or urinary tract infections.
Videourodynamic study will be performed by standard procedures using a 6 Fr dual channel catheter and an 8 Fr rectal balloon catheter. Cystometric study will be performed with normal saline at a filling rate of 20 ml/min. All descriptions and terminology in this report are in accordance with the recommendations of the International Continence Society. After the videourodynamic study, 40ml KCl solution of 0.4M will be infused slowly into the bladder and the test will be regarded as positive when painful (of ≧2 VAS score) or urgency sensation (urgency severity score increased by ≧1) is elicited compared to normal saline infusion during urodynamic study.
This study will be performed in Hualien Tzu chi General.The study should be approved by the Institutional Review Board (IRB) and ethics committee of the university and will be registered in ClinicalTrial.gov. Each patient will be informed about the study rationale and procedures, and written, informed consent will be obtained before treatment.
Eligible patients will be admitted for the treatment. They will be randomly assigned to receive intravesical injection of 100U of BoNT-A (BOTOX, Allergan, Irvine, CA, USA) into the trigone (the treatment group) or suburothelium (the comparative group) immediately followed by cystoscopic hydrodistention under intravenous general anesthesia in the operation room. Blood (10ml) and urine samples (30ml) will be collected before intravesical injection and after bladder hydrodistention. Bladder wall biopsies will also be performed after hydrodistention. The patients will be allocated to treatment or control group by the permuted block randomization code which is centrally controlled by a clinical pharmacist who prepares the solution for injection. The intravesical injection was performed by a urology attending doctor without recording the injection mode in the medical chart. The principle investigator, patients, and study nurse did not know the injection mode to the patients' bladder to keep the study in a double-blind condition.
Each vial of BoNT-A will be diluted with 10 ml of normal saline, resulting in 10U BoNT-A per 1.0 ml. Patients assigned for suburothelial BoNT-A injections received 20 injections in the bladder body whereas those assigned trigonal injections will receive 10 sites injections at the trigonal area (5 injections behind interureteric ridge and 5 inside the trigone). The injection needle will be inserted about 1mm into the urothelium at the bladder wall, using a 23 gauge needle and rigid cystoscopic injection instrument (22 Fr, Richard Wolf, and Knittlingen, Germany). Cystoscopic hydrodistention will be performed to an intravesical pressure of 80 cm water for 15 minutes and the maximal bladder capacity (MBC) under hydrodistention will be recorded. Bladder biopsies will be taken at the four sites about 2cm lateral and posterior to the ureteral orifice after hydrodistention.
After the BoNT-A injections, a 14 Fr urethral Foley catheter will be indwelled for one night and patients will be discharged on the next day. Oral antibiotics will be prescribed for 7 days. Patients will be followed up in the outpatient clinic 2 weeks and 4 weeks later. Then the patients will be followed up at out-patient clinic at 2 weeks, 4 weeks and 8 weeks.
Data from the 3-day voiding diary and symptom inventory using the O'Leary-Sant symptom score, as well as information on FBC, daily urinary frequency, nocturia, and pain VAS will be recorded at baseline, 2 weeks, 4 weeks, and 8 weeks. The largest voided volume in the 3-day voiding diary will be considered as a measure of FBC. At 8-week follow-up after the intravesical injection patients will be questioned of the current bladder condition and a urodynamics study with KCl test will be performed.
The urodynamic study will be performed at baseline and 12 weeks after intravesical treatment. The urodynamic parameters include first sensation of bladder filling (FSF), urge sensation (US), cystometric bladder capacity (CBC), detrusor pressure (Pdet), maximum flow rate (Qmax) during voiding and postvoid residual (PVR). KCl test will also be performed.
The primary end-point of this study is the reduction of bladder pain at 8-week follow-up. If patient has a reduction of VAS pain score of 2 or more, they will be considered as successfully treated. The treatment outcome will also be assessed by the global response assessment (GRA) to evaluate the overall perception of treatment result. The result will be considered as excellent when patients report improvement in the GRA by >2 or patients become free of bladder pain (VAS=0). The outcome will be considered improved if there is improvement in the GRA by =1. Patients with excellent and improved results will be considered as having subjectively successful result.
The results of voiding diary, urodynamic study, IC symptom score and pain VAS will be compared between baseline and 8-week end-point. Long-term successful results will be assessed by self-reported improved GRA and pain VAS at 6 months and further. Data will be compared between treatment and placebo groups. A p-value of less than 0.05 will be considered statistically significant.
If patients still feel bladder pain and unsuccessful results at the end-point, repeated BoNT-A injection will be given at 3 months in the same procedure. At the same time, bladder biopsy, urine and blood samples will also be collected for further study. . If patient does not want to receive repeat BoNT-A injection, intravesical hyaluronic acid instillations will be proceeded.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Hann-Chorng HC Kuo, M.D.
- Phone Number: 2113 886-3-8561825
- Email: hck@tzuchi.com.tw
Study Contact Backup
- Name: Dong-Ling DL Tang, Miss
- Phone Number: 2117 886-3-8561825
- Email: hck@tzuchi.com.tw
Study Locations
-
-
-
Hualien, Taiwan, 970
- Recruiting
- Buddhist Tzu Chi General Hospital
-
Contact:
- Tang, Miss
- Phone Number: 2117 886-3-8561825
- Email: don_lin86@yahoo.com.tw
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients have been diagnosed as IC/BPS based on characteristic symptoms and cystoscopic findings of glomerulations, petechia, or mucosal fissures after hydrodistention
- Patients have been treated with at least two types of treatment modalities including non-steroid anti-inflammatory drugs, oral PPS, intravesical instillation of heparin, hyaluronic acid, or tricyclic antidepressant for at least 6 months but the symptoms remained unchanged or relapsed.
- Patients who have bladder pain VAS of 3 or greater
Exclusion Criteria:
- Patients conditions not meeting the inclusion criteria of NIDDK
- Patients with Hunner's ulcer
- Patients with active urinary tract infection
- Patients who cannot keep a 3-day voiding diary prior to treatment
- Patients who do not sign informed consent form
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intravesical suburothelial injection
Patients assigned for suburothelial injections received 100 U of onabotulinumtoxinA in 20 sites injected in the bladder body on treatment day and follow-up
|
Each vial of onabotulinumtoxinA will be diluted with 10 ml of normal saline, resulting in 10U onabotulinumtoxinA per 1.0 ml.
Patients assigned for suburothelial BoNT-A injections received 20 injections in the bladder body whereas those assigned trigonal injections will receive 10 sites injections at the trigonal area (5 injections behind interureteric ridge and 5 inside the trigone).
Other Names:
|
Active Comparator: Intravesical trigonal injection
Patients assigned trigonal injections will receive 100U of onabotulinumtoxinA at 10 sites injected at the trigonal area (5 injections behind interureteric ridge and 5 inside the trigone) on treatment day and follow-up.
|
Each vial of onabotulinumtoxinA will be diluted with 10 ml of normal saline, resulting in 10U onabotulinumtoxinA per 1.0 ml.
Patients assigned for suburothelial BoNT-A injections received 20 injections in the bladder body whereas those assigned trigonal injections will receive 10 sites injections at the trigonal area (5 injections behind interureteric ridge and 5 inside the trigone).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction of bladder pain visual analog scale (VAS)
Time Frame: baseline to 8 weeks
|
Evaluation of the change of VAS from baseline to 8 weeks
|
baseline to 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Interstitial cystitis symptom index (ICSI)
Time Frame: baseline to 8 weeks
|
Evaluation of the change of ICSI froim baseline to 8 weeks
|
baseline to 8 weeks
|
Functional bladder capacity
Time Frame: baseline to 8 weeks
|
The change of maximal bladder capacity in voiding diary from baseline to 8 weeks
|
baseline to 8 weeks
|
Maximum flow rate (Qmax)
Time Frame: baseline to 8 weeks
|
The change of Qmax from baseline to 8 weeks
|
baseline to 8 weeks
|
Voided volume
Time Frame: baseline to 8 weeks
|
Thde change of voided volume from baseline to 8 weeks
|
baseline to 8 weeks
|
Postvoid residual volume
Time Frame: baseline to 8 weeks
|
The change of postvoid residual volume from baseline to 8 weeks
|
baseline to 8 weeks
|
Interstitial cystitis problem index (ICPI)
Time Frame: baseline to 8 weeks
|
Evaluation of the change of ICPI from baseline to 8 weeks
|
baseline to 8 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Hann-Chorng HC Kuo, M.D., Department of Urology, Buddhist Tzu Chi General Hospital, Hualien
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urologic Diseases
- Urinary Bladder Diseases
- Cystitis
- Cystitis, Interstitial
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- Neuromuscular Agents
- Botulinum Toxins, Type A
- abobotulinumtoxinA
Other Study ID Numbers
- BuddhistTCGH2003-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bladder Pain Syndrome
-
NYU Langone HealthCompletedInterstitial Cystitis Bladder Pain SyndromesUnited States
-
IRCCS Policlinico S. MatteoCompletedInterstitial Cystitis, Bladder Pain Syndrome, Quality of LifeItaly
-
University of Sao Paulo General HospitalGuangzhou Women and Children's Medical Center; Beijing Fangshan District Maternal... and other collaboratorsCompletedInterstitial Cystitis | Painful Bladder Syndrome | Bladder Pain SyndromeBrazil
-
University Hospital Inselspital, BerneCompletedOveractive Bladder | Cystitis, Interstitial | Painful Bladder Syndrome | Chronic Pelvic Pain SyndromeSwitzerland
-
Shanghai Institute of Acupuncture, Moxibustion...CompletedPainful Bladder SyndromeChina
-
Johns Hopkins UniversityWithdrawnInterstitial Cystitis | Painful Bladder Syndrome | Prostatitis | Chronic Prostatitis | Bladder Pain SyndromeUnited States
-
Cantonal Hospital, FrauenfeldCompletedOveractive Bladder | Interstitial Cystitis | Bladder Pain SyndromeSwitzerland
-
University Hospital Inselspital, BerneTerminatedBladder Pain Syndrome | Chronic Pelvic Pain SyndromeSwitzerland
-
Aquinox Pharmaceuticals (Canada) Inc.UnknownInterstitial Cystitis | Painful Bladder Syndrome | Bladder Pain Syndrome | Chronic Interstitial CystitisUnited States, Belgium, Canada, Czechia, Denmark, Hungary, Latvia, Netherlands, Poland, Romania, Spain, United Kingdom
-
AllerganRecruitingInterstitial Cystitis/Bladder Pain Syndrome (IC/BPS)United States, Canada
Clinical Trials on intravesical onabotulinumtoxinA injection
-
Michael Zell, MDNot yet recruitingOveractive Bladder | Benign Prostatic HyperplasiaUnited States
-
Ain Shams UniversityCompletedInterstitial Cystitis | Painful Bladder Syndrome (PBS)Egypt
-
Menoufia UniversityNot yet recruitingOveractive Bladder | Bladder Outlet Obstruction | BPH | Intravesical Botox | ThuLEP
-
Henan Cancer HospitalRecruitingIntraoperative Complications | Perfusion; Complications | High-Risk, Non-Muscle Invasive Bladder Urothelial CarcinomaChina
-
Rennes University HospitalCompletedIntensive Care Unit SyndromeFrance
-
National Taiwan University HospitalTerminated
-
Dartmouth-Hitchcock Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at Birmingham and other collaboratorsRecruitingOveractive Bladder | Urinary Incontinence in Old Age | Urgency Urinary IncontinenceUnited States
-
Anhembi Morumbi UniversityActive, not recruitingBladder Pain Syndrome | Interstitial Cystitis, ChronicBrazil
-
The University of Western AustraliaRoyal Perth Hospital; Fiona Stanley Hospital; Perth Urology ClinicCompletedSpinal Cord InjuriesAustralia
-
Loma Linda UniversityCompletedUrinary Bladder, Overactive | Urinary Incontinence, UrgeUnited States